Blood Tests Detect Early Cognitive Decline, Informing Dementia Risk Mitigation

Biomarker blood tests can identify early signs of cognitive decline in midlife adults without a dementia diagnosis. This detection is based on elevated levels of beta-amyloid and tau proteins, which are indicators of Alzheimer's disease.

Individuals with these elevated biomarkers demonstrated lower processing speeds and executive function. A five-year follow-up revealed a 2.5 to 4 times increased risk of rapid decline in verbal memory and a 3 to 4 times increased risk of rapid decline in processing speed for this group.

The findings suggest that positive biomarker tests

The findings suggest that positive biomarker tests, though not common, correlate with worse cognition and greater decline. This early identification could support the initiation of lifestyle modifications aimed at reducing dementia risk.

Such tests may also provide a more concrete basis for discussions about modifiable risk factors with clinicians. The ability to detect these proteins decades before clinical symptoms emerge could enable earlier interventions.